echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > BeiGene reached a partnership to develop innovative treatments for gastric cancer

    BeiGene reached a partnership to develop innovative treatments for gastric cancer

    • Last Update: 2020-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 3, leap therapeutics and beigene jointly announced that they had reached an exclusive option and license agreement on the clinical development and promotion of DKK1 targeted antagonist dkn-01 developed by leap in Asia (excluding Japan), Australia and New Zealand In addition, leap announced a $27 million equity financing agreement with Baiji Shenzhou and two institutional investors Dkn-01 is a humanized monoclonal antibody against DKK1 protein DKK1 is a protein that regulates Wnt signaling pathway and is highly expressed in many tumors It can help maintain tumor microenvironment with immunosuppressive effect around tumor Previously, dkn-01 combined with keytruda has achieved positive results in clinical trials for the treatment of DKK1 overexpressed advanced gastric esophageal junction adenocarcinoma / gastric cancer ▲ DKK1 can promote tumor growth by maintaining tumor microenvironment (photo source: leap website) Under the terms of the agreement, leap will receive an advance payment of $3 million from Baekje, which will receive an exclusive license to develop and promote dkn-01 in Asia (excluding Japan), Australia and New Zealand If baichi decides to exercise its option based on the results of subsequent preliminary proof of concept tests, leap will be eligible for an additional payment In addition, leap is eligible for potential milestone payments of up to $132 million, as well as dkn-01's share of sales in the licensed area As part of a $27 million equity investment being made simultaneously, Baekje will make a $5 million equity investment in leap During the selection period, leap agreed to carry out research on the combination therapy composed of dkn-01 and the PD-1 antibody tislilizumab developed by Baiji Shenzhou Leap plans to evaluate the efficacy of dkn-01 and tirelizumab combined therapy in about 40 patients with second-line DKK1 overexpression of gastric and esophageal junction adenocarcinoma / gastric cancer In addition, leap plans to evaluate the efficacy of dkn-01 in combination with tirelizumab and chemotherapy in about 20 patients with first-line adenocarcinoma / gastric cancer of the gastroesophageal junction Leap expects to launch these clinical trials in the first half of 2020 "We are very happy to explore the combination therapy of anti PD-1 antibody tirelizumab and dkn-01 So far, dkn-01 has been active in the combination of gastric cancer patients defined by biomarkers and immunosuppressive checkpoint inhibitors Our partnership with leap therapeutics is another example of our commitment to developing innovative therapies to meet unmet medical needs in Asia and around the world " Dr Christopher K mirabelli, President and CEO of leap therapeutics, said: "cooperation on the further development of dkn-01 has always been our primary strategic focus Baiji Shenzhou is an ideal partner of leap therapeutics They have rich experience in tumor drug development in the Asia Pacific region Their expertise and products will support our efforts to meet the far unmet medical needs in esophageal / gastric, gynecological and other cancers " A kind of
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.